Pfizer Inc. (PFE) on Thursday announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA in combination with XTANDI in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer.
The study met its primary endpoint, with the combination demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared to placebo plus XTANDI. The results exceeded the pre-specified hazard ratio target of 0.63, with most patients remaining progression-free at the time of analysis.
The treatment also showed consistent benefits in patients with both BRCA and non-BRCA HRR gene alterations.
Pfizer shares closed at $27.32 on Wednesday, down 0.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.